Post‐thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long‐term cross‐sectional follow‐up of RE‐COVER study patients
Key result
Dabigatran treatment for venous thromboembolism was associated with a similar long-term prevalence of post-thrombotic syndrome compared to warfarin (OR 1.1; 95% CI 0.6-1.8 after DVT).
Why the study?
Rivaroxaban has been suggested to reduce post-thrombotic syndrome risk compared to warfarin after DVT, but this had not been evaluated for oral direct thrombin inhibitors like dabigatran.
Does dabigatran reduce the long-term prevalence of post-thrombotic syndrome compared to warfarin in patients with venous thromboembolism?
Population
349 patients with acute DVT and/or PE randomized in Canada, Norway, and Sweden
Comparison
Dabigatran vs warfarin
Design
Cross-sectional follow-up study of randomized phase III trial patients
Follow-up
Mean 8.7 years
Authors
Discussion
Loading...
Member takes
Implication
No difference in PTS or HRQoL after dabigatran versus warfarin; leaves open whether DOACs differentially affect PTS risk.
Study Design
Type
Cross-Sectional (n=349)
Randomization
randomized
Multicenter
Yes
Structured PICO
Does dabigatran reduce the long-term prevalence of post-thrombotic syndrome compared to warfarin in patients with venous thromboembolism?
P
Population
349 patients with acute DVT and/or PE previously randomized to dabigatran or warfarin in the RE-COVER studies, assessed at a mean follow-up of 8.7 years.
E
Exposure
Dabigatran
C
Comparator
Warfarin
O
Outcome
Long-term prevalence of post-thrombotic syndrome (PTS) assessed by the patient-reported Villalta scale (PRV)patient reported
Main Result
Odds Ratio: 1.1 (95% CI 0.6–1.8)
In a long-term cross-sectional follow-up of the RE-COVER studies, dabigatran and warfarin showed similar rates of post-thrombotic syndrome, recurrent VTE, and health-related quality of life.
Cite This Study
Wik et al. (2021) conducted a cross-sectional in acute DVT and/or pulmonary embolism (PE) (n=349). Dabigatran vs. Warfarin was evaluated on long-term prevalence of post-thrombotic syndrome (PTS) (OR 1.1, 95% CI 0.6-1.8). Dabigatran treatment for venous thromboembolism was associated with a similar long-term prevalence of post-thrombotic syndrome compared to warfarin (OR 1.1; 95% CI 0.6-1.8 after DVT).